A detailed history of Verition Fund Management LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Verition Fund Management LLC holds 36,675 shares of FATE stock, worth $86,919. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,675
Holding current value
$86,919
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$3.26 - $7.08 $119,560 - $259,659
36,675 New
36,675 $120,000
Q3 2023

Nov 14, 2023

BUY
$2.02 - $5.04 $106,361 - $265,376
52,654 New
52,654 $111,000
Q4 2022

Feb 14, 2023

BUY
$9.86 - $23.83 $125,655 - $303,689
12,744 New
12,744 $128,000
Q4 2021

Feb 14, 2022

SELL
$47.84 - $64.34 $610,199 - $820,656
-12,755 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$59.27 - $95.73 $542,676 - $876,503
-9,156 Reduced 41.79%
12,755 $756,000
Q2 2021

Aug 16, 2021

BUY
$67.25 - $92.52 $1.47 Million - $2.03 Million
21,911 New
21,911 $1.9 Million

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $230M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.